Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | CDK5 | Q00535 | 13/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 13/20 | 0.41 |
| ▸ | CDK1 | P06493 | 9/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 8/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 8/20 | 0.39 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | PDE8A | O60658 | 3/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3714056 | 0.78 | KDM4E (0.37) | PIK3CDCDK5CDK5R1CRHR1 | |
| SCHEMBL3714054 | 0.78 | KDM4E (0.37) | PIK3CDCDK5CDK5R1CRHR1 | |
| SCHEMBL864208 | 0.78 | TLR8 (0.33) | PIK3CD | |
| SCHEMBL864178 | 0.74 | HTR7 (0.39) | PIK3CDCRHR1 | |
| SCHEMBL15184778 | 0.74 | HTR7 (0.39) | PIK3CDCRHR1 | |
| SCHEMBL864207 | 0.73 | ALDH1A1 (0.38) | PIK3CDCRHR1 | |
| SCHEMBL15184782 | 0.73 | KDM4E (0.35) | PIK3CDCRHR1 | |
| SCHEMBL863915 | 0.71 | CDK5 (0.39) | CDK5CDK5R1CDK1CCNB1CCNB2 | |
| SCHEMBL864127 | 0.70 | HTR7 (0.38) | PIK3CDCRHR1 | |
| SCHEMBL15184770 | 0.70 | HTR7 (0.38) | PIK3CDCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885CDK5 92/4885CDK5R1 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.